AbbVie Inc
SIX:ABBV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
AbbVie Inc
SIX:ABBV
|
US |
|
General Electric Co
TSX:GE
|
US |
Intrinsic Value
The intrinsic value of 
AbbVie Inc (ABBV) under the Base Case is 82.84 CHF per share.
Compared with the current market price of 96.65 CHF, the stock appears
Overvalued by 14% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What AbbVie Does
AbbVie is a pharmaceutical company that develops and sells prescription medicines. Its business is built around branded drugs for conditions such as immune disorders, cancer, eye disease, and other serious illnesses. It also works on research and development to create new treatments and support its long-term drug portfolio.
- Headquarters
- United States of America US
- Employees
- 57 000
- IPO date
- Jan 2, 2013
AbbVie has a wide economic moat
Patents prevent rivals from copying AbbVie’s protected medicines and competing mainly on price. Protection across several treatments helps the company defend its profits without relying on a single drug.
Read the full moat analysis
Revenue & Expenses Breakdown
AbbVie Inc
Earnings Waterfall
AbbVie Inc
The intrinsic value for AbbVie Inc (ABBV) under the Base Case is 82.84 CHF.
Compared with the current market price of 96.65 CHF, the stock appears Overvalued by 14% .
